Screening and studies of new targets for fibromyalgia by chemical methods

化学方法筛选和研究纤维肌痛新靶点

• 批准号: 21700436
• 负责人: SAWA Chika
• 金额: $ 2.83万
• 依托单位: Showa University (2010)St.Marianna University School of Medicine (2009)
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21700436/
• 关键词: 疼痛; 線維筋痛症; 神経疾患; ケミカルバイオロジー; 神経

Fibromyalgia Syndrome (FMS) is a chronic condition characterized by widespread pain and tenderness on examination, along with symptoms of sleep disorder, fatigue, and cognitive difficulties. FMS occurs in about 2 percent of the population in the United States and Japan (i.e. about two million patients are expected in Japan). Women are much more likely to develop the disorder than men, and the risk of FMS increases with age. FMS often begin after a physical or emotional trauma, but there is no blood test or biomarker that can conclusively determine the disease. It is reported that Gabapentin and Pregabalin has been worked very well for many FMS patients. But molecular mechanism of these two medicines for FMS is still unclear.We planed to screen interacting proteins of these two drugs, and study medicinal actions of nervous system in particular.To be concrete, we synthesized a new Gabapentin Fmoc-derivative and immobilized 2 kinds of Gabapentin derivatives to magnetic nano-beads and screen for interacting proteins by affinity purification from mouse brain extract.

纤维肌痛综合征（FMS）是一种慢性病，其特征是检查时疼痛和压痛，以及睡眠障碍，疲劳和认知困难的症状。 FMS发生在美国和日本的大约2％的人口中（即日本预计将有200万患者）。女性比男性更有可能发展这种疾病，而FMS的风险随着年龄的增长而增加。 FMS通常是在身体或情感创伤之后开始的，但是没有血液检查或生物标志物可以最终决定该疾病。据报道，Gabapentin和Pregabalin对于许多FMS患者的效果很好。但是，这两种针对FMS的分子机制仍不清楚。我们计划筛选这两种药物的相互作用蛋白质，尤其是研究神经系统的药物作用。要具体，我们将一种新的Gabapentin FMOC衍生品合成了新的Gabapentin FMOC衍生品，并通过启发型nano型蛋白质与脑相互作用，从而使两种类型的Gabapent蛋白通过启发蛋白进行了启发。

项目成果

線維筋痛症患者における血清中リゾホスファチジルコリン濃度の上昇

纤维肌痛患者血清溶血磷脂酰胆碱浓度升高

• 发表时间: 2009
• 作者: Xie W;Uchida H;Nagai J;Ueda M;Chun J;Ueda H.;植田弘師;植田弘師;西依倫子;西依倫子;佐々木恵太;内田仁司;永井潤;永井潤;植田弘師;松下洋輔;井上 誠;内田仁司;Ueda H;植田弘師;植田弘師;植田弘師;澤智華
• 通讯作者: 澤智華

Seeking gene candidates responsible for developmental origins of health and disease

• DOI: 10.1111/j.1741-4520.2011.00315.x
• 发表时间: 2011-09-01
• 期刊: CONGENITAL ANOMALIES
• 影响因子: 1.3
• 作者: Ogawa, Tetsuo;Rakwal, Randeep;Shioda, Seiji
• 通讯作者: Shioda, Seiji

Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease

• DOI: 10.3851/imp1699
• 发表时间: 2011-01-01
• 期刊: ANTIVIRAL THERAPY
• 影响因子: 1.2
• 作者: Araya, Natsumi;Takahashi, Katsunori;Yamano, Yoshihisa
• 通讯作者: Yamano, Yoshihisa

Increased serum levels of lysophosphatidylcholine in fibromyalgia patients.

纤维肌痛患者血清溶血磷脂酰胆碱水平升高。

• 期刊: Annals of the Rheumatic Diseases (in submitting)
• 作者: Sawa C.;Oka H.;Yamano Y.;Aoki J.;Ueda H.;Nishioka K.
• 通讯作者: Nishioka K.

Establishment of a superior mouse model for infantile neuroaxonal dystrophy bearing a point mutation in Pla2γ6 which shows early disease onset.

建立了具有 Pla2γ6 点突变的婴儿神经轴索营养不良的优质小鼠模型，该突变显示疾病的早期发作。

• 发表时间: 2009
• 期刊: The American Journal of Pathology 175(6)
• 作者: Wada H;Yasuda T;Miura I;Watabe K;Sawa C.;Kamijuku H;Kojo S;Taniguchi M;Nishino I;Wakana S;Yoshida H;Seino K.
• 通讯作者: Seino K.